SK61599A3 - Disintegrating oral pharmaceutical formulation - Google Patents

Disintegrating oral pharmaceutical formulation Download PDF

Info

Publication number
SK61599A3
SK61599A3 SK615-99A SK61599A SK61599A3 SK 61599 A3 SK61599 A3 SK 61599A3 SK 61599 A SK61599 A SK 61599A SK 61599 A3 SK61599 A3 SK 61599A3
Authority
SK
Slovakia
Prior art keywords
pharmaceutical composition
binder
tablet
sildenafil
mouth
Prior art date
Application number
SK615-99A
Other languages
English (en)
Slovak (sk)
Inventor
Cristi Bell-Huff
Thomas Francis Dolan
Angela Carol Gatlin Hausberger
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SK61599A3 publication Critical patent/SK61599A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Silicon Polymers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK615-99A 1998-05-15 1999-05-06 Disintegrating oral pharmaceutical formulation SK61599A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8564698P 1998-05-15 1998-05-15

Publications (1)

Publication Number Publication Date
SK61599A3 true SK61599A3 (en) 2000-12-11

Family

ID=22193027

Family Applications (1)

Application Number Title Priority Date Filing Date
SK615-99A SK61599A3 (en) 1998-05-15 1999-05-06 Disintegrating oral pharmaceutical formulation

Country Status (32)

Country Link
US (1) US20020002172A1 (hr)
EP (1) EP0960621A3 (hr)
JP (1) JPH11349483A (hr)
KR (1) KR19990088249A (hr)
CN (1) CN1251758A (hr)
AP (1) AP9901534A0 (hr)
AR (1) AR016481A1 (hr)
AU (1) AU753478B2 (hr)
BG (1) BG103396A (hr)
BR (1) BR9902086A (hr)
CA (1) CA2272042A1 (hr)
CO (1) CO5060503A1 (hr)
DZ (1) DZ2786A1 (hr)
EA (1) EA002830B1 (hr)
GT (1) GT199900061A (hr)
HN (1) HN1999000066A (hr)
HR (1) HRP990144A2 (hr)
HU (1) HUP9901606A2 (hr)
ID (1) ID23299A (hr)
IS (1) IS5046A (hr)
MA (1) MA26629A1 (hr)
NO (1) NO992339L (hr)
NZ (1) NZ335772A (hr)
OA (1) OA11040A (hr)
PA (1) PA8472901A1 (hr)
PE (1) PE20000546A1 (hr)
PL (1) PL333118A1 (hr)
SG (1) SG79255A1 (hr)
SK (1) SK61599A3 (hr)
TR (1) TR199901077A3 (hr)
YU (1) YU21999A (hr)
ZA (1) ZA993338B (hr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020033A1 (fr) * 1998-10-05 2000-04-13 Eisai Co., Ltd. Comprimes se delitant immediatement dans la cavite buccale
EP1161255A4 (en) * 1999-03-08 2002-07-17 Merck & Co Inc METHOD AND MEANS FOR TREATING ERECTILE DYSFUNCTION
JP2002539165A (ja) * 1999-03-16 2002-11-19 ペンテツク・フアーマシユーテイカルズ・インコーポレイテツド 舌下またはバッカル投与により送出されるシルデナフィルの制御放出
AU3574500A (en) * 1999-03-25 2000-10-16 Yuhan Corporation Rapidly disintegrable tablet for oral administration
KR100344198B1 (ko) * 1999-10-08 2002-07-19 일양약품주식회사 실데나필 시트레이트의 속효제형
CA2420461C (en) 2000-09-06 2008-08-12 Tanabe Seiyaku Co., Ltd. Preparations for oral administration
US6733781B2 (en) 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
IN192750B (hr) * 2000-12-15 2004-05-15 Ranbaxy Lab Ltd
US6544552B2 (en) * 2001-01-11 2003-04-08 Particle And Coating Technologies, Inc. Method of producing porous tablets with improved dissolution properties
EP1226818A1 (en) * 2001-01-26 2002-07-31 Pfizer Products Inc. Pharmaceutical dosage forms with enhanced cohesive and compressibility properties
CA2449163C (en) * 2001-05-09 2010-07-13 Bayer Healthcare Ag New use of 2-phenyl-substituted imidazotriazinones
LV12978B (en) * 2001-09-07 2003-05-20 Ivars Kalvins Pharmaceutical composition
WO2003028706A1 (fr) * 2001-09-28 2003-04-10 Sanwa Kagaku Kenkyusho Co.,Ltd Double comprime a desintegration rapide
US7118765B2 (en) 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
SE0202365D0 (sv) * 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
WO2004073729A1 (ja) 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
CN1758930B (zh) 2003-03-27 2010-06-09 株式会社新日本科学 鼻腔用粉末药剂喷药装置
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
US7670624B2 (en) 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
JP4922762B2 (ja) * 2004-08-10 2012-04-25 株式会社新日本科学 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
MX2008000087A (es) * 2005-06-23 2008-03-18 Schering Corp Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5.
KR20080056250A (ko) * 2005-09-29 2008-06-20 바이엘 헬스케어 아게 비뇨기 장애의 치료를 위한 ｐｄｅ 억제제 및 이들의 조합
EP2116264B1 (en) 2006-12-26 2017-09-27 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
KR20130122023A (ko) * 2007-02-12 2013-11-06 디엠아이 바이오사이언시스 인코포레이티드 트라마돌의 부작용을 감소시키는 방법
CN101711153A (zh) * 2007-06-13 2010-05-19 拜耳先灵制药股份公司 用于治疗听觉损伤的pde抑制剂
FR2932682B1 (fr) * 2008-06-23 2013-07-12 Bionetwork Nouvelles formes pharmaceutiques a effet rapide et les utilisations des compositions pharmaceutiques ainsi obtenus.
ES2588429T3 (es) * 2009-03-09 2016-11-02 Spi Pharma, Inc. Excipientes y sistemas de excipientes de compresión directa altamente compactables y durables
DE102009016584A1 (de) 2009-04-06 2010-10-07 Ratiopharm Gmbh Schmelztablette, enthaltend ein Sildenafil-Salz
EP2429495A4 (en) * 2009-05-15 2014-01-22 Shin Nippon Biomedical Lab Ltd INTRANASAL PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PHARMACOKINETICS
GB2472327B (en) * 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
WO2011030351A2 (en) 2009-09-03 2011-03-17 Rubicon Research Private Limited Taste - masked pharmaceutical compositions
EP2338474A1 (de) 2009-12-23 2011-06-29 Ratiopharm GmbH Oral dispersible Tablette enthaltend kompaktierte Sildenafil-Base
DE102010024866A1 (de) * 2010-06-24 2011-12-29 Pharmatech Gmbh Formulierung zur Geschmacksmaskierung
MY163288A (en) * 2011-02-11 2017-08-30 Ctc Bio Inc Sildenafil-free base-containing film preparation and method for producing same
KR101418406B1 (ko) * 2011-08-24 2014-07-10 한미약품 주식회사 실데나필 유리 염기를 포함하는 구강 붕해정
MX366768B (es) * 2011-12-08 2019-07-17 Laboratorios Liomont S A De C V Tableta orodispersable de sildenafil y metodo para preparar la misma.
KR102239291B1 (ko) 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
CN105769887B (zh) * 2014-12-23 2019-04-30 上海复星星泰医药科技有限公司 一种复方果糖二磷酸钠果糖口崩片及其制备方法
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
CN114246835A (zh) * 2022-01-05 2022-03-29 河北龙海药业有限公司 一种枸橼酸西地那非口腔崩解片的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2246013A1 (de) * 1972-09-20 1974-03-28 Boehringer Mannheim Gmbh Verfahren zur herstellung von poroesen tabletten
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
DE19532142A1 (de) * 1995-08-31 1997-03-06 Siemens Ag Verfahren und Vorrichtung zur Regelung eines vierdimensionalen Vektors einer Strecke mittels eines wertediskreten Stellgliedes mit begrenzter Schaltfrequenz
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
WO1998053819A1 (fr) * 1997-05-29 1998-12-03 Mochida Pharmaceutical Co., Ltd. Agent therapeutique destine a traiter l'anerection
TW542719B (en) * 1998-02-23 2003-07-21 Pfizer Res & Dev Method of treating impotence due to spinal cord injury
US6124461A (en) * 1998-05-26 2000-09-26 Saint Louis University, Health Services Center, Research Administration Compounds, compositions, and methods for treating erectile dysfunction
JP2002539165A (ja) * 1999-03-16 2002-11-19 ペンテツク・フアーマシユーテイカルズ・インコーポレイテツド 舌下またはバッカル投与により送出されるシルデナフィルの制御放出

Also Published As

Publication number Publication date
TR199901077A2 (en) 1999-12-21
AP9901534A0 (en) 1999-06-30
EP0960621A3 (en) 2000-01-05
BR9902086A (pt) 2000-05-02
NO992339L (no) 1999-11-16
DZ2786A1 (fr) 2003-12-01
TR199901077A3 (tr) 1999-12-21
CN1251758A (zh) 2000-05-03
PE20000546A1 (es) 2000-07-07
AR016481A1 (es) 2001-07-04
EA199900373A2 (ru) 1999-12-29
HN1999000066A (es) 1999-09-29
EA002830B1 (ru) 2002-10-31
NO992339D0 (no) 1999-05-14
SG79255A1 (en) 2001-03-20
HUP9901606A2 (en) 2002-09-28
BG103396A (bg) 2000-01-31
PA8472901A1 (es) 2000-09-29
HU9901606D0 (en) 1999-07-28
GT199900061A (es) 2000-10-14
NZ335772A (en) 2000-12-22
KR19990088249A (ko) 1999-12-27
EP0960621A2 (en) 1999-12-01
CA2272042A1 (en) 1999-11-15
YU21999A (sh) 2002-03-18
EA199900373A3 (ru) 2000-08-28
HRP990144A2 (en) 2000-02-29
US20020002172A1 (en) 2002-01-03
JPH11349483A (ja) 1999-12-21
AU2812699A (en) 1999-11-25
CO5060503A1 (es) 2001-07-30
PL333118A1 (en) 1999-11-22
ID23299A (id) 2000-04-05
ZA993338B (en) 2000-11-14
AU753478B2 (en) 2002-10-17
MA26629A1 (fr) 2004-12-20
IS5046A (is) 1999-11-16
OA11040A (en) 2003-01-01

Similar Documents

Publication Publication Date Title
SK61599A3 (en) Disintegrating oral pharmaceutical formulation
RU2193879C1 (ru) Фармацевтическая композиция для лечения острых нарушений
JP3190299B2 (ja) 迅速に分解する改良多粒子錠剤
JP2721219B2 (ja) 医薬組成物
US20110081389A1 (en) Composition comprising a mixture of active principles, and method of preparation
CN1136838C (zh) 固体、快速崩解的西替利嗪制剂
JP2003534270A (ja) 速放錠及びその製造方法
US20040166162A1 (en) Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
JPH01313420A (ja) 医薬咀しゃく錠組成物
JPWO2005055989A1 (ja) 薬物含有粒子および該粒子を含む固形製剤
JP4699350B2 (ja) 味マスキング被覆粒子、その調製方法および前記被覆粒子を含有する口腔内崩壊錠剤
SK287812B6 (sk) Tuhý farmaceutický prípravok rozpustný v ústach
JP2003176242A (ja) 速崩壊性圧縮成型物及びその製造法
KR100604034B1 (ko) 암로디핀 유리염기를 함유한 구강 속붕해정 및 그의 조성물
KR102060738B1 (ko) 에스오메프라졸 유리염기 또는 그의 알칼리염을 포함하는 고미가 차폐된 약학 제제 및 이의 제조방법
CA1219216A (en) Ph independent controlled release tablets
KR100503949B1 (ko) 염산 온단세트론의 쓴맛을 효과적으로 은폐한 경구용 구강속붕해정 조성물
CZ159199A3 (cs) Farmaceutický přípravek rozpadající se v ústech a způsob léčení sexuální dysfunkce
WO2004089343A1 (en) Water soluble tablets
EP1608341A1 (en) Water-soluble tablets of metformin
JP5241681B2 (ja) アムロジピン含有粒子およびそれからなる口腔内崩壊錠
SK50212011U1 (sk) Stable particulate pharmaceutical composition of solifenacin or its salt, mixture for its preparation and tablet comprising same
ZA200506028B (en) Composition comprising a mixture of active principles, and method of preparation